CLOV · Clover Health Investments, Corp. /De

Track CLOV — free

$4.56 +0.18 (+4.00%)

Russell 2000 member Rebalance outlook locked

Market Cap

$2.25B

531.16M

Volume · Oct 5 2.01M Avg daily vol (3M) 4.34M

Up next

Next earnings call

Nov 4, 2026 Est · unconfirmed · in 4 wks

Latest filing: 10-Q

filed Aug 7, 2026

Q2 2026 earnings call transcript

call held Aug 5, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$2.48B

Trailing 12 months

Net income (TTM)

−$18.36M

Trailing 12 months

Revenue growth YoY

+55.6%

Year over year

Operating margin

-0.7%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

3.3%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+7.2%

Year over year · more shares

Price change (1Y)

+73.1%

Trailing year

Short interest

4.4%

Latest settlement · 5.2 days to cover

View all 115 metrics

AI Brief

Q2 FY26 earnings call · Aug 5, 2026

Q2 FY26

TL;DR. Clover Health reported 48% Medicare Advantage membership growth alongside $28M Q2 GAAP net income, raised full-year 2026 guidance across all metrics citing strong cohort maturation, and signaled increasing confidence in 2027 supported by a 4.5-star payment year.

Bullish

+ Raised full-year 2026 guidance across all metrics including revenue, gross profit, Adjusted EBITDA, GAAP net income and membership
+ Medicare Advantage membership grew 48% year-over-year in Q2 with $743M revenue up 56%
+ Achieved $28M Q2 GAAP net income and $41M Adjusted EBITDA, both materially improved year-over-year
+ 4.5-star payment year confirmed following court ruling, providing additional flexibility for 2027 bids
+ Adjusted SG&A improved ~220 bps as a percent of revenue, demonstrating operating leverage at scale

Bearish

− CMS has appealed the district court ruling on star rating recalculation, creating uncertainty around the 4.5-star outcome
− Company expects a typical seasonal Q4 adjusted EBITDA loss after positive Q3
− Outpatient utilization trends remain elevated from prior years despite moderation from March peak

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice

Overall

Buy

SellHoldBuy

Technical Neutral Momentum Very Strong Sentiment Bullish Fundamentals Excellent Quant / Vol Very High

Market backdrop VIX 15.3 · calm Equity put/call 0.58

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg +32%

above

Price vs 50-day avg −0%

below

RSI (14) 48

neutral

MACD trend Negative

52-week position 72%

mid-range

Volume (OBV) Bearish div.

distributing

Momentum

relative strength

Very Strong

1-month return +3%

trailing

6-month return +116%

trailing

YTD return +86%

this year

Relative strength +104%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $4 › 200d $3 — 50d above 200d

Institutional flow Accumulating

2 of 229 funds reported for Sep 30 · net +144 sh shares · +1 new

Insider flow Distributing

Net -$103.2K over 90 days · 100% sells

Short interest Falling

4.41% of float · ▼ -1.0% MoM · 5.2 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

229 holders — near 3-yr high, broad support

Squeeze score 61

elevated · 0–100

Fundamentals

Excellent

Revenue growth +40%

Y/Y

Gross margin 13%

expanding

EPS growth +38%

Y/Y

Free cash flow $-69.0M

Buyback $20.0M

authorized

Balance sheet $280.0M

net cash

Quant / Vol

risk profile

Very High

Volatility 66%

annualized · 1-yr

Max drawdown −56%

past year

ATR 4.8%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Latest guidance · from the 8-K filed Aug 5, 2026

Total revenues · Full Year 2026 Initiated $2.92B – $3B

prior FY $1.92B midpoint +53.8% Y/Y

Consolidated Gross profit · Full Year 2026 Initiated $525M – $555M

Adjusted EBITDA · Full Year 2026 Initiated $70M – $85M

GAAP Net income · Full Year 2026 Initiated $20M – $35M

Guided vs delivered · last 1 settled

Total revenues full year 2021

guided $1.42B – $1.47B

guided $1.42B – $1.47B $1.47B Beat +1.9%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral

2 · 4 · 1

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+32% Bullish

Price vs 50-day avg

−0% Neutral

RSI (14)

48 Neutral

MACD trend

Negative Bearish

52-week position

72% Neutral

Volume (OBV)

Bearish div. Bearish

Market signals — smart money & positioning

Bullish · 3 of 6

Trend (MA cross) No cross

50d $4 › 200d $3 — 50d above 200d

Institutional flow Accumulating

2 of 229 funds reported for Sep 30 · net +144 sh shares · +1 new

Insider flow Distributing

Net -$103.2K over 90 days · 100% sells

Short interest Falling

4.41% of float · ▼ -1.0% MoM · 5.2 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

229 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $2 Now $4 · 72% Range high $5

vs 200-day avg +32% vs 50-day avg 0%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
Adjusted EBITDA non-GAAP	$40.92M	Three Months Ended June 30, 2026 filing	—
Adjusted Net income non-GAAP	$40.35M	Three Months Ended June 30, 2026 filing	—
Adjusted SG&A (non-GAAP) non-GAAP	$112.09M	Three Months Ended June 30, 2026 filing	—
GAAP → non-GAAP reconciliation GAAP Total SG&A (GAAP) 124.44M -9.08M Stock-based compensation -3.27M Non-recurring legal expenses and settlements = Adjusted SG&A (non-GAAP) 112.09M
Adjusted SG&A (non-GAAP) as a percentage of Total revenues non-GAAP	15.1%	Three Months Ended June 30, 2026 filing	—
Average Medicare Advantage membership	156,840	Three Months Ended June 30, 2026 filing	—
Consolidated Gross profit (non-GAAP) non-GAAP	$153M	Three Months Ended June 30, 2026 filing	—
GAAP → non-GAAP reconciliation GAAP Net income (loss) (GAAP) 28M +54.14M Salaries and benefits +70.3M General and administrative expenses +564K Depreciation and amortization +0K Change in fair value of warrants = Consolidated Gross profit (non-GAAP) 153M
Insurance Benefits Expense (non-GAAP) non-GAAP	$646.06M	Three Months Ended June 30, 2026 filing	—
GAAP → non-GAAP reconciliation GAAP Insurance Net medical claims incurred, net (GAAP) 615.42M +30.64M Quality improvements = Insurance Benefits Expense (non-GAAP) 646.06M
Insurance Benefits Expense Ratio	87.6%	Three Months Ended June 30, 2026 filing	—
Net medical claims incurred per member	$1,254	the three months ended June 30, 2026 filing	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Healthcare Plans — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
CLOV Clover Health Investments, Corp. /De this stock	$2.25B	+86.4%	+40.3%	—	4.4%
UNH Unitedhealth Group Inc	$338.03B	+12.7%	+11.8%	—	1.5%
CVS CVS HEALTH Corp	$110.82B	+8.9%	+7.8%	22.9	1.3%
ELV Elevance Health, Inc.	$85.90B	+10.2%	+12.5%	17.5	2.5%
CI Cigna Group	$71.06B	-1.7%	+11.2%	11.1	2.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

230

% held: 30.0%
Reported: 2 of 229
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

150

View

Short & Settlement

Short Interest Falling

Shares short

23.4M

Days to cover: 5.2d
Change: -231.2K sh

View

Short Volume

Short vol %

40%

As of: Oct 2, 2026

Short Total

View

Fails to Deliver

FTD shares

100

Value: $429
As of: Sep 9, 2026

View

Off-Exchange

Off-exchange %

47.9%

Week of: Aug 31, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$103.2K

Buyers / Sellers: 0 / 1

Buyers Sellers

View

Financials

Revenue (FY)

$1.9B

Net income (FY): $-85.5M
EPS diluted: $-0.44

View

Buybacks

Authorized

$20.0M

View

Filings

SEC Filings

Latest

8-K/A

Filed: Sep 25, 2026
This year: 24

View

Proposed Sales

Value

$631.2K

Shares: 141.4K
Filed: Sep 24, 2026

View

Earnings & Events

Webcasts

Last webcast

Sep 15, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
CLOV	-2.5%	+2.9%	+115.8%	+1.6%	+86.4%
SPY	-0.2%	-0.5%	+12.2%	+0.9%	+12.9%
vs SPY	-2.2%	+3.4%	+103.6%	+0.7%	+73.5%

Capital returns

Buyback program · as of May 6, 2024

Authorized

$20.00M

Spent (derived)

—

Remaining

—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1801170 CUSIP 18914F103 13F (30d) 14 filings 9 filers Visit website Investor relations

CLOV · Clover Health Investments, Corp. /De

Price & Indicators

Up next

Metrics snapshot

AI Brief

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance

Capital returns